Merck/Daiichi Beef Up Regulatory Position For HER3 ADC
The two drug makers announced topline Phase III results for patritumab deruxtecan in EGFR-mutated NSCLC. The drug was hit by a complete response letter earlier this year.
The two drug makers announced topline Phase III results for patritumab deruxtecan in EGFR-mutated NSCLC. The drug was hit by a complete response letter earlier this year.